# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

B-Cell Lymphomas

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 11-20 of 2194 results.
Quikin CD19-CART in Patients With r/r B-cell Lymphoma
Status: Recruiting
Last Changed: Mar 16, 2020
First Received: Dec 30, 2019
Disease(s): B-cell Lymphoma
Intervention(s): CD19-Specific Chimeric Antigen Receptor T cells with PD1 knockout
Locations: the First Affliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China
Study of TG-1801 in Subjects With B-Cell Lymphoma
Status: Recruiting
Last Changed: Jun 11, 2020
First Received: Jan 15, 2019
Disease(s): B-Cell Lymphoma
Intervention(s): TG-1801
Locations: Olivia Newton-John Cancer Wellness & Research Centre, Heidelberg, Australia
The Alfred Hospital, Melbourne, Australia
TG Therapeutics Investigational Trial Site, Nedlands, Australia
Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)
Status: Completed
Last Changed: Nov 01, 2019
First Received: May 05, 2015
Disease(s): Marginal Zone B-cell Lymphoma
Intervention(s): bendamustine plus rituximab
Locations: Chonbuk National University Hospital, Jeonju, Jeollabuk-do, Korea, Republic of
Hallym University Medical Center, Anyang-si, Korea, Republic of
Chungnam National University, Daejeon, Korea, Republic of
Gachon University Gil Medical Center, Incheon, Korea, Republic of
Gyeongsang National University Hospital, Jinju, Korea, Republic of
... and 7 other locations.
Refractory Diffuse Large B-cell Lymphoma
Status: Completed
Last Changed: Sep 10, 2018
First Received: Sep 10, 2018
Disease(s): Diffuse Large B-cell Lymphoma
Locations: Centre Hospitalier Lyon Sud, Pierre-Bénite, France
Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B Cell Lymphoma.
Status: Recruiting
Last Changed: Apr 26, 2019
First Received: Apr 26, 2019
Disease(s): B Cell Lymphoma
Intervention(s): Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T cells
Locations: The first affiliated hospital of Zhejiang University, Hangzhou, Zhejiang, China
Novel Autologou CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma
Status: Active, not recruiting
Last Changed: Feb 15, 2019
First Received: Aug 22, 2017
Disease(s): B Cell Lymphoma
Intervention(s): CAR-T
Locations: The first affiliated hospital of Zhejiang University, Hangzhou, Zhejiang, China
CD19-targeting CAR T Cells for B Cell Lymphoma
Status: Withdrawn
Last Changed: Jul 16, 2020
First Received: Sep 14, 2015
Disease(s): B Cell Lymphoma
Intervention(s): CD19-targeting CAR T Cells infusion
Locations: Central laboratory in Fuda cancer hospital, Guangzhou, Guangdong, China
CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma.
Status: Unknown status
Last Changed: May 17, 2017
First Received: May 10, 2017
Disease(s): B Cell Lymphoma
Intervention(s): Fludarabine, Cyclophosphamide, CD19 CART
Locations: The Second People's Hospital of Shenzhen, Shenzhen, Guangdong, China
Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma
Status: Recruiting
Last Changed: Jul 17, 2020
First Received: Dec 03, 2018
Disease(s): B-cell Lymphoma
Intervention(s): Axicabtagene Ciloleucel, Fludarabine, Cyclophosphamide
Locations: Banner Health MD Anderson Cancer Center, Gilbert, Arizona, United States
City of Hope, Duarte, California, United States
UCLA, Los Angeles, California, United States
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
University of Chicago, Chicago, Illinois, United States
... and 8 other locations.
The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma
Status: Unknown status
Last Changed: Apr 05, 2017
First Received: Apr 05, 2017
Disease(s): B Cell Lymphoma
Intervention(s): Cyclophosphamide, Fludarabine, CART-19
Locations: Henan Cancer Hospital, Zhengzhou, Henan, China